BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 17062778)

  • 21. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
    Knights KM; Rowland A; Miners JO
    Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.
    Salonen JS; Nyman L; Boobis AR; Edwards RJ; Watts P; Lake BG; Price RJ; Renwick AB; Gómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb PS; Lewis DF; Taavitsainen P; Pelkonen O
    Drug Metab Dispos; 2003 Sep; 31(9):1093-102. PubMed ID: 12920164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
    Dehal SS; Kupfer D
    Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.
    Mutlib AE; Goosen TC; Bauman JN; Williams JA; Kulkarni S; Kostrubsky S
    Chem Res Toxicol; 2006 May; 19(5):701-9. PubMed ID: 16696573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
    Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes.
    Kong TY; Kim JH; Kwon SS; Cheong JC; Kim HS; In MK; Lee HS
    Arch Pharm Res; 2017 Jun; 40(6):727-735. PubMed ID: 28484907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.
    Sauer C; Peters FT; Schwaninger AE; Meyer MR; Maurer HH
    Chem Res Toxicol; 2008 Oct; 21(10):1949-55. PubMed ID: 18778087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic biotransformation of non-psychotropic phytocannabinoids and activity screening on cytochromes P450 and UDP-glucuronosyltransferases.
    Havlasek J; Vrba J; Zatloukalova M; Papouskova B; Modriansky M; Storch J; Vacek J
    Toxicol Appl Pharmacol; 2023 Oct; 476():116654. PubMed ID: 37574147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
    Doehmer J; Weiss G; McGregor GP; Appel K
    Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro metabolism of eupatilin by multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes.
    Lee HS; Ji HY; Park EJ; Kim SY
    Xenobiotica; 2007 Aug; 37(8):803-17. PubMed ID: 17701830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells.
    Reilly CA; Ehlhardt WJ; Jackson DA; Kulanthaivel P; Mutlib AE; Espina RJ; Moody DE; Crouch DJ; Yost GS
    Chem Res Toxicol; 2003 Mar; 16(3):336-49. PubMed ID: 12641434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
    Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
    Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.
    Linnet K; Olesen OV
    Drug Metab Dispos; 1997 Dec; 25(12):1379-82. PubMed ID: 9394027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro metabolism of a new oxazolidinedione hypoglycemic agent utilizing liver microsomes and recombinant human cytochrome P450 enzymes.
    Agrawal AK; Hop CE; Pang J; Silva Elipe MV; Desai RC; Leung KH; Franklin RB
    J Pharm Biomed Anal; 2005 Feb; 37(2):351-8. PubMed ID: 15708677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone.
    Nishiyama T; Kobori T; Arai K; Ogura K; Ohnuma T; Ishii K; Hayashi K; Hiratsuka A
    Arch Biochem Biophys; 2006 Oct; 454(1):72-9. PubMed ID: 16949544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
    Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
    Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthraquinone biocolourant dermocybin is metabolized whereas dermorubin is not in in vitro liver fractions and recombinant metabolic enzymes.
    Yli-Öyrä J; Juvonen RO; Lehtonen M; Herrala M; Finel M; Räisänen R; Rysä J
    Basic Clin Pharmacol Toxicol; 2024 Jun; 134(6):846-857. PubMed ID: 38664998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
    Roy P; Yu LJ; Crespi CL; Waxman DJ
    Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.